Kashyap Priyanka V, Singh Dharmendra, Nair Akhiya, Jaiswal Aditi, Pandey Vaibhav
Department of Neurology, AIIMS Bhopal, Madhya Pradesh, India.
Department of Community Medicine, AIIMS Bhopal, Madhya Pradesh, India.
Ann Neurosci. 2025 Jul 29:09727531251357377. doi: 10.1177/09727531251357377.
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder affecting motor neurons and is characterised by a diverse range of clinical manifestations. With the understanding of its pathophysiology, many treatments have emerged in last two decades. This study aims to evaluate the impact of intravenous Edaravone on Amyotrophy Lateral Sclerosis Functional Rating Scale (ALS-FRS) scores and patient survival outcomes of Amyotrophic Lateral Sclerosis patients in Central India.
This retrospective study was conducted over a span of 2.5 years and included patients diagnosed with definitive or probable ALS, as per the revised El Escorial criteria. The effects of intravenous (IV) Edaravone on ALS-FRS-R scores were compared between two groups: the intervention group (patients who received IV Edaravone) and the non-intervention group (patients who did not receive IV Edaravone). Data collected included demographic details and ALS-FRS-R scores that were recorded at baseline after each treatment cycle, for a total six cycles. These scores were compared with those of the control group at the corresponding time points. Survival outcomes were also evaluated between the two groups and side effect profile of the drug was also noted.
Data of ALS patients (definitive and probable) were screened, and 62 patients were enrolled, of which 12 were excluded, thus there were 25 ALS patients in the intervention group and 25 patients in the non-intervention group. The two groups were matched for demographic parameters and the ALS-FRS scores were noted at the baseline at each cycle till 6 cycles and compared. It was inferred that the scores were not significant statistically ( > .001) among the two groups, nor did the survival rates vary significantly.
Intravenous Edaravone therapy had no beneficial effect on the ALS-FRS score in the intervention group when compared to the non-intervention group, nor did the survival rates improve. Keywords: Amyotrophic lateral sclerosis, Edaravone Therapy, ALS FRS Score.
肌萎缩侧索硬化症（ALS）是一种影响运动神经元的进行性神经退行性疾病，其临床表现多样。随着对其病理生理学的认识，在过去二十年中出现了许多治疗方法。本研究旨在评估静脉注射依达拉奉对印度中部肌萎缩侧索硬化症患者的肌萎缩侧索硬化功能评定量表（ALS-FRS）评分和生存结局的影响。
这项回顾性研究历时2.5年，纳入了根据修订的埃尔埃斯科里亚尔标准诊断为明确或可能患有ALS的患者。比较了两组静脉注射（IV）依达拉奉对ALS-FRS-R评分的影响：干预组（接受IV依达拉奉的患者）和非干预组（未接受IV依达拉奉的患者）。收集的数据包括人口统计学细节和在每个治疗周期后基线记录的ALS-FRS-R评分，共六个周期。将这些评分与对照组在相应时间点的评分进行比较。还评估了两组之间的生存结局，并记录了药物的副作用情况。
对ALS患者（明确和可能）的数据进行了筛选，共纳入62例患者，其中12例被排除，因此干预组有25例ALS患者，非干预组有25例患者。两组在人口统计学参数上进行了匹配，并在每个周期的基线记录ALS-FRS评分，直至6个周期并进行比较。推断两组之间的评分在统计学上无显著差异（>.001），生存率也无显著差异。
与非干预组相比，静脉注射依达拉奉治疗对干预组的ALS-FRS评分没有有益影响，生存率也没有提高。关键词：肌萎缩侧索硬化症，依达拉奉治疗，ALS FRS评分。
